At this point, the selection of these biomarkers (TLR4, TLR9 and Resolvin E1), especially the extreme scarcity of the studies and the fact that all of them are animal studies, is to examine whether the possible hypothetical mechanisms of a condition such as primary sarcopenia, which is less confounding than secondary sarcopenia, are valid in humans. The gene discussed is TLR4; the disease is sarcopenia.